Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Host genetic factors influencing drug disposition and response to HIV treatment
2006-003425-81Phase 4Completed
- Sponsor
- University of Liverpool
- Start
- Nov 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of saquinavir, indinavir, nelfinavir, atazanavir, ritonavir and 12 more in human immunodeficiency virus infection (HIV), sponsored by University of Liverpool. Primary endpoints: Change in CD4 count at 24 weeks and Change in viral load at 24 weeks. Started Nov 2006; status: completed.
02
Drugs
saquinavirindinavirnelfinaviratazanavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-003425-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003425-81.